The group discontinues its first-generation antisense Huntington’s projects on disappointing efficacy, leaving its next-gen asset with much to prove.
But the company focused on a modified intent-to-treat analysis of its pivotal trial.
The company might finally become an oncology player.
The group’s antisense project is the only game in town for Usher syndrome, but its latest trial is not a slam-dunk.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
As Biogen heads towards important depression data, Sanofi looks to oncology for growth.
Boehringer says its inhaled antibody could reach the patients IV antibodies cannot, but will be “very happy” if it isn’t needed.